What is iECURE?
iECURE is a specialized gene editing company dedicated to the development of innovative therapies that utilize mutation-agnostic in vivo gene insertion, commonly referred to as knock-in editing. By focusing on liver disorders, the company addresses complex genetic conditions that have historically lacked effective treatment options. Its market position is defined by a commitment to precision medicine and the application of advanced molecular tools to correct genetic defects at the source. The company's platform is designed to be versatile, potentially allowing for the treatment of a broad spectrum of liver-based diseases through a single, scalable therapeutic framework.
How much funding has iECURE raised?
iECURE has raised a total of $115M across 2 funding rounds:
Series A
$50M
Series A
$65M
Series A (2021): $50M with participation from OrbiMed and Versant Ventures
Series A (2022): $65M led by OrbiMed, Novo Holdings, LYFE Capital, and Versant Ventures
Key Investors in iECURE
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms.
Versant Ventures
Versant Ventures partners with exceptional entrepreneurs to build and fund innovative biotechnology companies, leveraging extensive scientific expertise and global laboratory facilities.
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term investments in the life sciences industry.
What's next for iECURE?
With the recent influx of capital, iECURE is poised to enter a critical phase of operational scaling and clinical validation. The strategic roadmap likely involves advancing its lead candidates through preclinical milestones and preparing for initial human trials. The company's focus will remain on optimizing its gene insertion efficiency and ensuring the safety profile of its therapeutic delivery mechanisms. As it navigates the complex regulatory landscape of gene therapy, iECURE will likely prioritize partnerships that enhance its manufacturing capabilities and clinical trial infrastructure. The continued support from its investor syndicate provides the necessary runway to transform its scientific breakthroughs into tangible, life-altering medical interventions, solidifying its role as a key player in the next generation of genetic medicine.
See full iECURE company page
